Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) FCF Yield % : 14.96 (As of Apr. 28, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Ironwood Pharmaceuticals FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Ironwood Pharmaceuticals's Trailing 12-Month Free Cash Flow is $183.2 Mil, and Market Cap is $1,224.1 Mil. Therefore, Ironwood Pharmaceuticals's FCF Yield % for today is 14.96%.

The historical rank and industry rank for Ironwood Pharmaceuticals's FCF Yield % or its related term are showing as below:

IRWD' s FCF Yield % Range Over the Past 10 Years
Min: -28.17 Med: -4.42 Max: 20.55
Current: 14.96

During the past 13 years, the highest FCF Yield % of Ironwood Pharmaceuticals was 20.55%. The lowest was -28.17%. And the median was -4.42%.

IRWD's FCF Yield % is ranked better than
94.17% of 1080 companies
in the Drug Manufacturers industry
Industry Median: -0.65 vs IRWD: 14.96

Ironwood Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was 30.30%.

Ironwood Pharmaceuticals FCF Yield % Historical Data

The historical data trend for Ironwood Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ironwood Pharmaceuticals FCF Yield % Chart

Ironwood Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

0.17

9.13

13.85

14.34

10.24

Ironwood Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial															16.60	19.62	8.42	8.62	7.97

Competitive Comparison of Ironwood Pharmaceuticals's FCF Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Ironwood Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ironwood Pharmaceuticals's FCF Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ironwood Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Ironwood Pharmaceuticals's FCF Yield % falls into.

Ironwood Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Ironwood Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	183.154	/	1788.68976
	=	10.24%

Ironwood Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	35.623	*	4	/	1788.68976
	=	7.97%

Ironwood Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Ironwood Pharmaceuticals FCF Yield % Related Terms

Thank you for viewing the detailed overview of Ironwood Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ironwood Pharmaceuticals Inc (NAS:IRWD) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

I76:Germany I76:Germany

Address

100 Summer Street, Suite 2300, Boston, MA, USA, 02110

Website

https://www.ironwoodpharma.com

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Executives

Marla L Kessler	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Andrew Davis	officer: SVP, Chief Business Officer	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sravan Kumar Emany	officer: SVP, Chief Financial Officer	100 SUMMER ST, SUITE 2300, BOSTON MA 02109
Ronald Silver	officer: Principal Accounting Officer	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Minardo John	officer: Chief Legal Officer	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Thomas A Mccourt	officer: Chief Commercial Officer	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Michael Shetzline	officer: CMO,SVP,Head-Res&Drug	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jason Rickard	officer: SVP, Chief Operating Officer	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Mark G Currie	officer: Chief Scientific Officer	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Julie Mchugh	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Sarissa Capital Management Lp	10 percent owner	660 STEAMBOAT ROAD, GREENWICH CT 06830
Alexander J Denner	director	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Edward P Owens	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Gina Consylman	officer: Chief Accounting Officer	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Kilroy Conor	officer: SVP, GC & Secretary	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110